In the first such judgment since the 1980s, Justice Moshinsky has granted an interlocutory injunction to prevent TMA...
Interlocutory Injunction To Restrain Further Threats Of Patent Infringement Proceedings Granted In Car Park Scrap
read more
Home / News / Pearce IP Blog
ALL BLOGS BY
Emily Dwyer
Emily provides broad paralegal services including litigation support services, legal research, IP monitoring and tracking services, and document management.
A self professed “legal junkie” she loves exploring legal arguments and is excited about new legal developments.
See Emily's full profile
Pearce IP BioBlast w/e 8 April 2022
31 March 22 | Fresenius Kabi announced that it has bought a majority stake (55%) in mAbxience, a company specialising...
Australian Government commits to claim damages from originator pharmaceutical companies where generic entry is unduly delayed
In its 2022-23 Budget, the Coalition Government has stated that it will continue to fund litigation against originator...
Pearce IP BioBlast w/e 1 April 2022
28 Mar 22 | Aurobindo announced that it will acquire certain business assets from Veritaz (the supplier of branded...
AU Budget 22-23: Highlights for Health, Pharma/Biopharma, Life Sciences & Agribusiness
In the Coalition Government’s Budget for the financial year 2022-23, it sets out the investments that it would make...
Pearce IP BioBlast w/e 25 March 2022
19 Mar 22 | US | Amgen and Pfizer settled their pegfilgrastim (Neulasta®) dispute Amgen Inc v Hospira Inc (D. Del.,...
Pearce IP BioBlast w/e 18 March 2022
14 Mar 22 | OcyonBio announced that it has entered into a manufacturing and operations agreement with Biosimilar...
High Court Puts The Brakes On Damages Recovery During Patent Term Extension
Introduction The decision of the High Court in H. Lundbeck A/S v Sandoz Pty Ltd [2022] HCA 4 (Lundbeck) last week...
Pearce IP BioBlast w/e 11 March 2022
03 Mar 22 | US | FDA announced a new funding opportunity for the BsUFA III Regulatory Science Program to support...
Reminder – new .au domain names coming to Australia from 24 March 2022
Priority given to owners of corresponding Australian domain names in the .au race
We previously wrote that, from 24 March 2022, individuals, businesses and organisations with an Australian presence...
Pearce IP BioBlast w/e 25 February 2022
18 Feb 22 | Celltrion released two data sets on the subcutaneous (SC) form of Remsima® (biosimilar infliximab)....
Pearce IP BioBlast 18 February 2022
11 Apr 22 | CA | Celltrion announced the launch of Yuflyma® (high-concentration, low-volume, citrate-free and...
Pearce IP BioBlast w/e 11 February 2022
07 Feb 22 | The International Generic and Biosimilar medicines Association (IGBA) announced that it has established a...
Pearce IP BioBlast w/e 04 February 2022
01 Feb 22 | JAMP Pharma announced the creation of a new division BIOJAMP™ dedicated to biosimilars. The creation of...
Pearce IP BioBlast® f/e 31 January 2022
18 Jan 22 | Alvotech announced $21 million in additional commitments for private placement (PIPE) of Oaktree II common...
Pearce IP BioBlast® w/e 14 January 2022
10 Jan 22 | CA | Alvotech and JAMP Pharma announced that Health Canada has approved Simlandi (high-concentration,...